Clinical Trials 下面列出了当前开展的临床试验。93 研究 Cardiovascular Diseases and Cardiac Surgery (仅限开放研究). 根据地点、状态和其他条件对此研究列表进行过滤。 A Study to Evaluate Exercise Capacity and Positive Airway Pressure Impact on Sleep Apnea in Heart Failure Rochester, Minn. The purpose of this study is to determine the prevalence of Obstructive Sleep Apnea (OSA) in HFpEF, and its clinical and hemodynamic correlates, and to determine the impact of intervention with CPAP therapy on exercise capacity and quality of life in HFpEF patients with OSA. Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms Rochester, Minn. Prospective, non-randomized, , multicenter study with two independent arms: * Primary Study Arm - TAAA and Pararenal aneurysms requiring only TAMBE System. Hypothesis-driven analysis. * Up to 65 additional subjects may be implanted in Continued Access Phase under the Primary Study Arm only * Secondary Study Arm - TAAA requiring TAMBE System and CTAG Device(s). Non hypothesis-driven analysis. Minimum: 122 implanted subjects. Maximum: 202 implanted subjects with up to 65 additional subjects implanted in Continued Access (Primary Study arm) A Repository of Atria Tissue for the Investigation of Atrial Pathophysiology in Patients with Atrial Fibrillation Rochester, Minn. The purpose of this study is to collect surgically removed atrial tissue for genetic, pathologic, metabolic, and molecular studies in patients with or without a history of atrial fibrillation. A Study to Evaluate Perceptions of Midline Sternotomy Scar in Children and Young Adults Rochester, Minn. The purpose of this study is to evaluate how children and young adults perceive their midline sternotomy scars (in terms of appearance, associated symptoms, consciousness, satisfaction with appearance/symptoms, and impact on quality of life)? A Study to Establish a Registry for the Pulmonary Hypertension Association Jacksonville, Fla. The objectives of this study are to measure and improve quality of care (including assessing differences in adherence to evidence-based guidelines and establishing benchmarks for health outcomes); determine the clinical effectiveness, comparative effectiveness, and cost effectiveness of treatment approaches; understand risk factors for outcomes and regional/center differences; and facilitate funded clinical trials of new therapies and collaboration with the PAH community at large, including providers, patients, and their caregivers. Study to Determine the Accuracy of a New Venous Air Plethysmograph in People with Normal, Incompetent, and Obstructed Venous Hemodynamics. Rochester, Minn. The purpose of this study is to determine the accuracy (sensitivity, specificity, negative predictive value, positive predictive value) of a new venous air plethysmograph in people with normal, incompetent, and obstructed venous hemodynamics. Post Approval Study for Treatment of Drug-resistant Adult Primary FSGS Using the LIPOSORBER® LA-15 System Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult and pediatric patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient is post renal transplantation. Treatment for FSGS is considered unsuccessful if the patient is unresponsive to standard therapy (e.g., at least 8 weeks of corticosteroids) and fails to achieve complete or partial remission. A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit. A Study to Evaluate DDP3 as a Predictor of Cardiogenic Shock in Patients Presenting with Cardiac Symptoms Rochester, Minn. The purpose of this study is to evaluate whether DDP3 identifies patients at early risk of cardiogenic shock presenting with STEMI in order to benefit from more aggressive cardiology scrutiny. A Study to Assess the Current FDA-approved AliveCor Kardia Device to Measure the QT/QTc in Patients Presenting to the Genetic Heart Rhythm Clinic Rochester, Minn. The purpose of this study is to assess the feasibility of using the current FDA-approved AliveCor Kardia device and their AliveCor Tripod device (FDA Approval pending) to measure the QT/QTc in patients presenting to the Genetic Heart Rhythm Clinic. Rivet PVS Therapy in Group 2C Rochester, Minn. The purpose of this study is to evaluate the safety, performance, and initial clinical efficacy of the Rivet PVS therapy in patients with symptomatic pulmonary hypertension. Pagination 临床研究 PrevPrevious Page Go to page 44 Go to page 55 Go to page 66 Go to page 77 Go to page 88 NextNext Page 医疗专业人员 Cardiovascular Diseases & Cardiac Surgery clinical-trials